UBE2I

Across TCGA pan-cancer cohorts, UBE2I Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBE2I data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher UBE2I Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated UBE2I expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC and PRAD are the cancer types where UBE2I Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.633	.019	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

UBE2I–UCEC (DFS)

Open the UCEC breakdown →